z-logo
Premium
Incidental acute prostatic inflammation is associated with a lower percentage of free prostate‐specific antigen than other benign conditions of the prostate: a prospective screening study
Author(s) -
ROWE EDWARD W.J.,
LANIADO MARC E.,
WALKER MARJORIE M.,
ANUP PATEL
Publication year - 2006
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06132.x
Subject(s) - medicine , prostate cancer , prostate , inflammation , prostate specific antigen , urology , prospective cohort study , asymptomatic , cancer , prostate biopsy , biopsy , oncology , gastroenterology
OBJECTIVE To evaluate the performance of percentage free/total prostate‐specific antigen (f/tPSA) as a screening tool for prostate cancer, and to assess the impact of prostatic inflammation on f/tPSA. PATIENTS AND METHODS Men aged 50–65 years were invited for prostate cancer screening. Biopsies were taken from men with a tPSA of ≥ 4 ng/mL, together with those with a tPSA of 1.1–3.99 ng/mL and a f/tPSA of ≤ 20%. Histological evidence of prostate cancer, acute inflammation, chronic inflammation, and benign prostatic tissue were noted in biopsy cores, together with the associated f/tPSA values. RESULTS The cancer detection rate was 4.3% (33/773). Evidence of inflammation was found in about half (87/175) of those biopsied. Men with acute inflammation (27/175, 15%) had significantly lower serum f/tPSA values (mean 13.4%) than those with chronic inflammation (mean 16.6%, P  = 0.002) and benign prostatic tissue (mean 15.7%, P  = 0.034), but were similar to men with prostate cancer (mean 15.3%, P  = 0.315). CONCLUSIONS In this prospectively screened cohort of men, there was a high incidence of asymptomatic inflammation on prostatic histology; f/tPSA values were significantly lower in men with acute inflammation. This might explain the variability of f/tPSA in improving specificity when used as a screening tool for prostate cancer, and might also reduce its effectiveness in differentiating tumours with more aggressive potential.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here